TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03612596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative visualization
Description: Participants use narrative visualization procedures to connect their step data to important events or feelings that occurred at the same time, then reflect on their behavior

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard self-regulation
Description: Participants self-monitor steps using a wearable device, app, and a hand-written step log
Study: NCT01805518

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Scelectium Tortuosum
Description: One arm has subjects 3 weeks on Scelectium Tortuosum 25gm po/d then 3 weeks off and then 3 weeks on Placebo.~The other arm has subjects 3 weeks on placebo, then 3 weeks off and then 3 weeks on Scelectium Tortuosum 25mg po/d.
Study: NCT00531115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab 5mg/ml
Description: Weekly administration of Cetuximab (initial infusion of 400 mg/m2 for 120 minutes followed by subsequent maintenance doses of 250 mg/m2 for 60 minutes) Oxaliplatin. 130 mg/m2 every three weeks. on day 1 for 4 cycles Capecitabine. 1000 mg/m2 twice daily (2.000 mg/m2 total daily dose) or 750 mg/m2 if Cl Cr=30-50 ml/min (1500 mg/m2 total daily dose) for two weeks (on days 1 to 14) followed by one week of rest (on days 15 to 21).~The patients will receive 4 cycles of cetuximab plus combination chemotherapy administered every 3 weeks in order to achieve a noticeable response. Then, oxaliplatin treatment will be stopped after a maximum of 4 infusions to prevent appearance of neuropathy and then followed by capecitabine 2 weeks out of 3, and cetuximab weekly as maintenance treatment.
Study: NCT02024074

Intervention type: OTHER
Group type: OTHER
Intervention: Sestamibi (Tc-MBI) scan of the breast
Description: Patients will be given 8mCi of Sestamibi intravenously. following which Sestamibi scan will be performed on the breast. Sestamibi scan will be done prior to any surgical procedure..
Study: NCT02067845

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Adapted Many Men, Many Voices (3MV) group level intervention
Description: The intervention will adapt the Many Men, Many Voices (3MV) group level intervention for MSM to address individual and social determinants of HIV/STI risk and vulnerability. This intervention involves 6 consecutive 2-3 hours sessions conducted at a weekend retreat. We will have 1 retreat in Calgary and 1 retreat in Toronto; each retreat will include 20 persons.~Based on the 3MV format, a draft template includes: Session 1: Intersectionality; Session 2: STI/HIV Prevention Among WSW and LBQ Women; Session 3: STI/HIV Risk Assessment and Prevention Options; Session 4: Relationship Issues; Session 5: Self-efficacy, Resilient Coping and Capacity for Change; Session 6: Social Support and Problem Solving to Maintain Change.~Delivery methods include discussion, role-plays and risk-reduction planning.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: A group-based HIV/STI prevention intervention for women who have sex with women
Study: NCT01260350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) tablets administered orally once daily
Study: NCT01763060

Intervention type: RADIATION
Intervention: CT scan

Intervention type: BEHAVIORAL
Intervention: Cognitive function

Intervention type: RADIATION
Intervention: MRI
Study: NCT02235064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Capsule containing crushed sertraline 50 mg tablets mixed with identically colored cellulose, with 4 day 25 mg taper

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule containing cellulose powder of same color as experimental arm
Study: NCT02194283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol - in single rising doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02844543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EYE-SYNC eye-tracking device
Description: The EYE-SYNC® portable eye-tracking system. The eye tracker is a handheld isolated display environment with embedded eye tracking sensors. The eye tracker is connected to a high-performance Windows tablet though a customized docking station. Included accessories with EYE-SYNC are a U.S. tablet power supply adapter and disposable sanitary masks. Participants are asked to follow a dot with their eyes, as the dot moves on the screen of the EYE-SYNC device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCAT-3
Description: The Symptom subtest of SCAT-3 assessment tool will be administered to participants.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Desktop Eye-Tracker
Description: Eye movements are recorded with an eye tracking system (Desktop Eye-Tracker, Eyelink CR, SR Research) with up to 1000 Hz temporal resolution. The target stimulus is presented on a computer screen approximately 50 cm from the participant. Participants are asked to follow a dot with their eyes, as the dot moves on the monitor screen of the desk-top eye-tracking device.
Study: NCT01041157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Neck muscle trainings effect on botulinum toxin efficiency
Study: NCT04082923

Intervention type: OTHER
Group type: OTHER
Intervention: Liquid meal
Description: Four-hour liquid mixed meal test

Intervention type: OTHER
Group type: OTHER
Intervention: Liquid meal
Description: Four-hour liquid mixed meal test

Intervention type: OTHER
Group type: OTHER
Intervention: Liquid meal
Description: Four-hour liquid mixed meal test

Intervention type: OTHER
Group type: OTHER
Intervention: Solid meal
Description: Four-hour solid mixed meal test

Intervention type: OTHER
Group type: OTHER
Intervention: Solid meal
Description: Four-hour solid mixed meal test

Intervention type: OTHER
Group type: OTHER
Intervention: Solid meal
Description: Four-hour solid mixed meal test
Study: NCT05863260

Intervention type: DRUG
Intervention: Treatment Group
Description: Treatment Group
Study: NCT04262089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (Keytruda)
Description: Pembrolizumab (Keytruda), 200mg IV Q3W for a total of 2 administrations per patient, integrated into standard-of-care protocol prior to surgery. Based on the well-established time lines, the interval between diagnosis and standard of care hysterectomy is sufficient to treat patients with two cycles of pembrolizumab without interfering with standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (Keytruda)
Description: Pembrolizumab (Keytruda), 200mg IV Q3W for a total of 2 administrations per patient, integrated into standard-of-care protocol prior to surgery. Based on the well-established time lines, the interval between diagnosis and standard of care hysterectomy is sufficient to treat patients with two cycles of pembrolizumab without interfering with standard of care.
Study: NCT03563963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% Injectable Solution
Description: Ropivacaine 0.5% will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2% Preservative-Free Injectable Solution
Description: Lidocaine 2% will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Air
Description: Air will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
Study: NCT03881189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SUNEKOS® 200
Description: The intradermal injection procedure was performed bilaterally, on the area around the eyes including the eyelids, using periosteal and subepidermal injection techniques. This injective procedure consists of micro-wheals of 0.2 ml just above the periosteum and micro-wheals of 0.1 ml very superficially, just under epidermis.
Study: NCT02501850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Treatment with liraglutide, exenatide or lixisenatide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Treatment with metformin and/or sulphonilurea
Study: NCT01991587

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose of quadrivalent VLP vaccine
Description: A single low dose of quadrivalent VLP vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium dose of quadrivalent VLP vaccine
Description: A single medium dose of quadrivalent VLP vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose of quadrivalent VLP vaccine
Description: A single high dose of quadrivalent VLP vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo
Study: NCT02089828

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autologous purified CD34+ cells

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: autologous peripheral blood mononuclear cells
Study: NCT01260350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) tablets administered orally once daily
Study: NCT03787745

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ischemic postconditioning
Description: After 60 seconds of reperfusion, ischemic postconditioning with an adequately sized balloon (60 reperfusion/60 seconds re-occlusion, four cycles) will be performed

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional
Description: State of the art primary PCI, however thrombectomy is not allowed
Study: NCT00470444

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transfusion with Red Blood Cells
Description: Units of donated Red blood cells

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 1 unit of donated red blood cells
Description: Units of red blood cells

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 1 unit of donated red blood cells
Description: Units of donated red blood cells
Study: NCT00851045

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Solution, IV, 180 mg/m2, Q14 days, Until PD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Solution, IV, 180 mg/m2, Q14 days, Until PD
Study: NCT05501418

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord mesenchymal stem cells
Description: UMSC01 cells will be IV infusion with 12 months of follow up after treatment.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Controlled normal saline
Description: Normal saline will be IV infusion with 12 months of follow up after treatment.
Study: NCT04144413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label Ikervis
Description: NOVA22007, IKERVIS® is a sterile, ophthalmic cationic oil-in-water emulsion containing 1mg/ml CsA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masked Ikervis
Description: NOVA22007, IKERVIS® is a sterile, ophthalmic cationic oil-in-water emulsion containing 1mg/ml CsA.

Intervention type: OTHER
Group type: OTHER
Intervention: Vehicle Comparator: Masked Vehicle
Description: Vehicle of IKERVIS® - sterile, ophthalmic cationic oil-in-water emulsion containing no active substance.
Study: NCT00851045

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil (bolus)
Description: Solution, IV, 400 mg/m2, Q14 days, Until PD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil (bolus)
Description: Solution, IV, 400 mg/m2, Q14 days, Until PD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil (infusional)
Description: Solution, IV, 2400 mg/m2, Q14 days, Until PD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil (infusional)
Description: Solution, IV, 2400 mg/m2, Q14 days, Until PD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin calcium
Description: Solution, IV, 400 mg/m2, Q14 days, Until PD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin calcium
Description: Solution, IV, 400 mg/m2, Q14 days, Until PD
Study: NCT03843489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEDLINE RENEWAL PULSE OXIMETRY SENSORS
Description: An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. Pulse oximetry monitoring is considered a standard physiological measurement and is used by clinicians in everyday situations to estimate arterial oxygen saturation. Because an arterial sample of blood is not required to make the measurement, the pulse oximeter can provide non-invasive real time information.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Reference CO-oximetry sensor
Description: A whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
Study: NCT02955355

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HYQVIA
Description: Participants received HYQVIA/HyQvia SC which contains both Immune Globulin Infusion 10% (Human) (IGI, 10%) and recombinant human hyaluronidase (rHuPH20).
Study: NCT00851045

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT-322
Description: Solution, IV, 2 mg/kg, Q7 days, Until PD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Solutions, IV, 5 mg/kg, Q14 days, Until PD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab Placebo (saline solution)
Description: Solution, IV, 0 mg/kg, On day 8 of a 2-week cycle, Until PD
Study: NCT00826683

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Enumeration of endothelial cell progenitor in peripheral blood by flow cytometry, Endothelial cell progenitor characterization by primary cell cultures

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Enumeration of endothelial cell progenitor in peripheral blood by flow cytometry, Endothelial cell progenitor characterization by primary cell cultures

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Enumeration of endothelial cell progenitor in peripheral blood by flow cytometry, Endothelial cell progenitor characterization by primary cell cultures
Study: NCT04538833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: monosialic gangliosides
Description: The experimental group received 80 mg of monosialic gangliosides (GM1) on days -1, 1, and 2 of albumin-bound paclitaxel(GM1 is a single infusion).
Study: NCT01835886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients will ascend and descend a flight of 10 steps
Description: Patients referred to pulmonary rehabilitation with documented lung disease will ascend and descend a flight of 10 steps for a period of 30 seconds
Study: NCT01027000

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic stem cell transplant
Study: NCT04461977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: True acupuncture
Description: The selection of acupuncture points is based on Traditional Chinese Medicine (Wen, 2011) and on previous studies (Jeong,2018; Bao,2018), selected as main points: bilateral baxie, SJ5, bafeng, KID3 and ST36. Modifications or additional secondary points may be indicated according to clinical judgment throughout treatment. The needles will be inserted at a depth of 10 - 15 mm, being gently manipulated to obtain de qi sensation. The needles will be left for 20 - 25 minutes. There will be once a week acupuncture treatment, for 8 consecutive weeks. The acupuncture needles will be sterile, disposable stainless steel needles size 0.20 x 30 mm, of Korean brand Dong Bang, Chungcheongnam-do.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Patients will receive needling at non-acupuncture points with superficial needling without manipulation to obtain de qi, located near the real points in the hands and feet. The needles will also be left for 20 - 25 minutes. There will be once a week acupuncture treatment, for 8 consecutive weeks. There will be once a week acupuncture treatment, for 8 consecutive weeks. The acupuncture needles will be sterile, disposable stainless steel needles size 0.20 x 30 mm, of Korean brand Dong Bang, Chungcheongnam-do.
Study: NCT02207920

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E Vaccine
Description: 600 mcg/mL to be administered as 1 mL intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E Vaccine
Description: 600 mcg/mL to be administered as 1 mL intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E Vaccine
Description: 600 mcg/mL to be administered as 1 mL intramuscular (IM) injection
Study: NCT04538833

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group received placebo on days -1, 1, and 2 of albumin-bound paclitaxel (placebo as a single infusion)
Study: NCT02110212

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: U/S Surgery and CCC
Description: Subjects will receive the standard of care for U/S cataract surgery and CCC to facilitate removal of the crystalline lens.
Study: NCT02207920

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E Vaccine
Description: 600 mcg/mL to be administered as 1 mL intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123 Vaccine
Description: 4 mg/mL to be administered as 1 mL IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123 Vaccine
Description: 4 mg/mL to be administered as 1 mL IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123 Vaccine
Description: 4 mg/mL to be administered as 1 mL IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123 Vaccine
Description: 4 mg/mL to be administered as 1 mL IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for DNA-HIV-PT123
Description: Sodium chloride for injection USP, 0.9%; administered as 1 mL IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for DNA-HIV-PT123
Description: Sodium chloride for injection USP, 0.9%; administered as 1 mL IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for AIDSVAX B/E
Description: Sodium chloride for injection USP, 0.9%; administered as 1 mL IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for AIDSVAX B/E
Description: Sodium chloride for injection USP, 0.9%; administered as 1 mL IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for AIDSVAX B/E
Description: Sodium chloride for injection USP, 0.9%; administered as 1 mL IM injection
Study: NCT02625103

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: blood samples for s-clozapine and s-desmethyl-clozapine analysis are collected at 10, 11, 12, 13 and 14 hours post evening-clozapine-administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: Registration of the exact time of drug administration. Also postponement of any morning clozapine administration until ended blood sampling.
Study: NCT04003116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen gas
Description: Supplementary oxygen during the first 48 hours added to conventional anticoagulant treatment. Patients will receive anticoagulant treatment according to updated guidelines.
Study: NCT02110212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FS Laser Surgery
Description: The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery.
Study: NCT00441610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gimatecan
Study: NCT03834779

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DOORS-CHW Intervention
Description: The behavioral intervention has been developed for a collaborative CHW and re-entry program intervention that targets HIV outcomes, substance use and recidivism in HIV+ jail releasees.~Participants will be randomized to the DOORS+CHW intervention versus TAU and all participants will undergo study follow-up visits at 3, 6 and 12 months. In other words, participants randomized to the intervention arm will meet with the CHW and a staff member from DOORS. One of the primary study aims is a randomized controlled trial of an intervention which has a reasonable probability of improving the health and well-being of the subject by improving linkage to social services and the HIV clinic. The control arm will receive standard of care (referrals to case management).
Study: NCT00386880

Intervention type: OTHER
Intervention: Sounds

Intervention type: OTHER
Intervention: Sounds